Concomitant administration of sitagliptin and rutin improves the adverse hepatic alterations in streptozotocin-induced diabetes mellitus in albino rats: an overview of the role of alpha smooth muscle actin
Abstract
Background: Diabetes mellitus (DM), one of the commonest worldwide metabolic conditions, is believed to be associated with an imbalance between oxidants and antioxidants. Sitagliptin is an oral anti-hyperglycaemic drug that blocks dipeptidyl peptidase 4 (DPP4). Rutin is a polyphenolic natural flavonoid which has antioxidant and anti-proliferative activity. The aim of the present work is to elucidate the concomitant effect of sitagliptin and rutin on the deleterious alterations in the liver of experimentally induced diabetes in rats.
Materials and methods: Fifty adult male albino rats, weighing 170–200 g were used. Rats were randomly divided into five groups (n = 10): group 1 (control group), the other four groups (groups II, III, IV and V) received a single i.p. injection of streptozotocin, 65 mg/kg body weight to induce diabetes; group II (diabetic), group III (diabetic and rutin administered), group IV (diabetic and sitagliptin administered), and group V (diabetic with sitagliptin and rutin concomitantly administered). Haematoxylin and eosin, Masson trichrome, periodic acid Schiff, immune-histochemistry: a-smooth muscle actin (a-SMA), histomorphometric analysis, liver enzymes and oxidants/anti-oxidants; malondialdehyde/glutathione and were done.
Results: Distorted hepatic architecture, dilatation, congestion of sinusoids and central veins as well as cytoplasmic vacuolations were remarkable changes in the diabetic group. There was extravasation of blood, diffuse fibrous tissue formation, increase in the mean values of liver enzymes, oxidative markers and a-SMA expression in the same group. The aforementioned changes were ameliorated in groups III and IV. Concomitant administration of sitagliptin and rutin resulted in marked enhancement of these hepatic alterations.
Conclusions: Combination of sitagliptin and rutin has an ameliorating effect on the hepatic deterioration induced by diabetes, which is better than either sitagliptin or rutin alone.
Keywords: streptozotocinliverdiabetesalpha smooth muscle actinsitagliptinrutin
References
- Ahmed OM, Moneim AA, Yazid IA, et al. Antihyperglycemic, antihyperlipidemic and antioxidant effects and the probable mechanisms of action of Ruta graveolens infusion and rutin in nicotinamide-streptozotocin-induced diabetic rats. Diabetol Croat. 2010; 39(1): 15–35.
- Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin: diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab. 2009; 23(4): 487–498.
- Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2): 194–206.
- Aschner P, Kipnes MS, Lunceford JK, et al. Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29(12): 2632–2637.
- Bancroft JD, Gamble M. Theory and Practice of Histological Techniques. 7th ed. Staining methods. Churchill Livingstone,, Edinburgh, London, Madrid, Melbourne, New York and Tokyo 2008.
- Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology. 2008; 15(2): 91–101.
- Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001; 21(3): 311–335.
- Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107(9): 1058–1070.
- Giampietro O, Giampietro C, Bartola LD, et al. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Drug Des Devel Ther. 2013; 7: 99–104.
- Haidara MA, Ibrahim MI, Sit EI, et al. Effect of a-tocopherol on glucose uptake and contractility in rat skeletal muscles. Med Sci Monv. 2003; 9(5): 214–217.
- Horn T, Junge J, Christoffersen P. Early alcoholic liver injury: changes of the Disse space in acinar zone 3. Liver. 1985; 5(6): 301–310.
- Hramiak IM, Finegoodk DT, Adams PC. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med. 1997; 20: 110–118.
- Hsu CY, Shih HY, Chia YC, et al. Rutin potentiates insulin receptor kinase to enhance insulin-dependent glucose transporter 4 translocation. Mol Nutr Food Res. 2014; 58(6): 1168–1176.
- Jeschke MG. The hepatic response to thermal injury: is the liver important for postburn outcomes? Mol Med. 2009; 15(9-10): 337–351.
- Júnior II, Barbosa Hd, Carvalho DCR, et al. Brazilian attenuated hyperglycemia, dyslipidemia, and prooxidant status in alloxan-induced diabetic rats. Scientific World J. 2017; 2017: 5275813.
- Liu Q, Pan R, Ding L, et al. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries. Int Immunopharmacol. 2017; 49: 132–141.
- Manaras K, Jongdee N, Uraporn V, et al. Effect of glabridin on collagen deposition in liver and amelioration of hepatocyte destruction in diabetes rats. Exp Ther Med. 2019; 18(2): 1164–1174.
- Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003; 17(1): 24–38.
- Masarone M, Rosato V, Dallio M, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018; 2018: 9547613.
- Meng XM, Chung ACK, Lan HY. Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond). 2013; 124(4): 243–254.
- Moustafa Hassan I, El-Gharabawy G, Moustafa AG. The effect of Sitagliptin (Januvia) on the liver of adult Albino rats in cases of experimental diabetes mellitus(Microscopic and laboratory studies). Egyptian J Hosp Med. 2012; 47(1): 260–278.
- Nakashima O, Kurogi M, Yamaguchi R, et al. Unique hypervascular nodules in alcoholic liver cirrhosis: identical to focal nodular hyperplasia-like nodules? J Hepatol. 2004; 41(6): 992–998.
- Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell. 2003; 112(4): 481–490.
- Pan PH, Lin SY, Wang YY, et al. Protective effects of rutin on liver injury induced by biliary obstruction in rats. Free Radic Biol Med. 2014; 73: 106–116.
- Rahimi R, Nikfar S, Larijani B, et al. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005; 59(7): 365–373.
- Rother KI. Diabetes treatment--bridging the divide. N Engl J Med. 2007; 356(15): 1499–1501.
- Soares JM, Pereira Leal AE, Silva JC, et al. Influence of flavonoids on mechanism of modulation of insulin secretion. Pharmacogn Mag. 2017; 13(52): 639–646.
- Tian S, Bilin Xu, Taolei C, et al. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Exp Ther Med. 2018; 16(4): 3121–3128.
- Uchida K. Future of toxicology: lipid peroxidation in the future: from biomarker to etiology. Chem Res Toxicol. 2007; 20(1): 3–5.
- Vanlangenakker N, Vanden Berghe T, Krysko DV, et al. Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med. 2008; 8(3): 207–220.
- Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013; 124(3): 139–152.
- Yilmaz Y, Senates E, Yesil A, et al. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. J Diabetes Complications. 2014; 28(3): 328–331.
- Yoo H, Ku SK, Baek YD, et al. Anti-inflammatory effects of rutin on HMGB1-induced inflammatory responses in vitro and in vivo. Inflamm Res. 2014; 63(3): 197–206.
- Zargar S, Wani TA, Alamro AA, et al. Amelioration of thioacetamide-induced liver toxicity in Wistar rats by rutin. Int J Immunopathol Pharmacol. 2017; 30(3): 207–214.
